Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2/Neu Positive|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Entinostat|OTHER: Laboratory Biomarker Analysis|DRUG: Lapatinib Ditosylate|BIOLOGICAL: Trastuzumab
Sponsor: National Cancer Institute (NCI)